Integrase Strand Transfer Inhibitors Play the Main Role in Greater Weight Gain Among Men With Acute and Early HIV Infection

Kuan-Sheng Wu,1,2 Christy Anderson,3 and Susan J. Little*  
1Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 2Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, and 3Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA

Background. The predictors of weight gain remain unclear in people with acute and early HIV infection (AEH).

Methods. Eligible antiretroviral-naïve men diagnosed with AEH from January 1, 2000, to December 31, 2019, were enrolled in an observational cohort study at the University California, San Diego. The study used multivariable mixed-effect linear regression models to analyze differences in the rate of weight gain over time between participants receiving early vs deferred antiretroviral therapy (ART) treatment, low vs high baseline CD4 count and HIV RNA, and different classes of ART.

Results. A total of 463 participants were identified, with mean CD4 cell count of 507 cells/μL and log HIV RNA of 5.0 copies/mL at study entry. There was no difference in the rate of weight gain between participants who did and did not receive ART within 96 weeks of incident HIV infection. Neither a baseline CD4 count of <350 cells/μL nor a baseline HIV RNA of >100,000 copies/mL was a predictor of weight gain. Compared with persons taking non-nucleoside reverse transcriptase inhibitor–based regimens, those who received integrase strand transfer inhibitor (INSTI)–based regimens showed greater weight gain over time.

Conclusions. Neither baseline CD4 count and HIV RNA nor early ART was associated with weight change in the first 96 weeks following incident HIV infection. Use of INSTI-based regimens represented a major driver of weight gain in men who initiated ART with relatively higher CD4 cell counts.

Keywords. acute and early HIV; antiretroviral therapy; HIV; integrase strand transfer inhibitor; weight gain.

The factors associated with weight change in people with HIV (PWH) have been thoroughly investigated [1–6]. Even without effective antiretroviral therapy (ART), PWH still show gradually increasing weight until late-stage disease [7, 8]. Once ART was initiated, weight gain among PWH was almost ubiquitous [1–4]. Factors associated with greater weight gain have included (1) a low CD4 count and high HIV RNA at ART initiation, (2) use of integrase strand transfer inhibitor (INSTI) and (3) tenofovir alafenamide (TAF), (4) Black race, and (5) female sex [1, 9–16]. However, the majority of participants in published studies have been people with chronic HIV infection. The trajectory of weight change and the factors that may influence weight gain remain unknown in people with acute and early HIV infection (AEH).

After ART initiation, the weight increase was once undoubtedly welcome because it represented a sign of recovery and was linked to lower mortality among people whose body mass index (BMI) was normal or below normal [17]. Independent of ART, rates of obesity have increased among PWH [2, 5, 18], with greater weight gain potentially contributing to undesirable metabolic and cardiovascular disorders [19–21].

The mechanisms of weight gain on ART are not fully understood. Some experts have considered the return-to-health phenomenon as a major driver, a process by which individuals with reduced weight recover to their pre-illness weight (ie, healthy weight) following ART initiation [22]. Several studies support the return-to-health phenomenon, including the finding that people with lower CD4 counts and higher HIV RNA levels had more significant weight gain after treatment [1, 12]; more weight gain was observed in the first year after ART initiation [4, 15]; and weight change in PWH approached HIV-uninfected comparators after 3 years of ART [2].

People with AEH have a shorter duration of infection than persons with chronic infection and may therefore demonstrate different weight trajectories with and without ART. By including AEH individuals who received early ART, we can
analyze the effect of ART on weight change in the earliest stage of HIV disease we can ever acquire at this time. This approach may also help minimize confounders caused by prolonged HIV infection. To better understand weight changes in people with AEH and identify potential factors associated with greater weight gain, we conducted a retrospective analysis of longitudinal weight data from an observational database.

**METHODS**

**Study Design and Participants**

Participants with AEH were identified at HIV screening programs of the Primary Infection Resource Consortium (PIRC) at the University of California San Diego (UCSD). Participants newly diagnosed with HIV infection were enrolled between January 1, 2000, and December 31, 2019. An estimated date of infection was calculated using serologic and virologic data, as previously described [23]. The current analysis was limited to adults (age ≥ 18 years) who were assigned male at birth. We chose not to include the individuals assigned female at birth because this population accounted for only 1.9% of all participants, which might prevent drawing any definite conclusion. Participants were followed according to the observational study schedule, and weight was measured each visit at the same clinic.

Data were collected from January 1, 2000, through July 31, 2020, and included baseline demographics (age, race, ethnicity), longitudinal clinical data (CD4 counts, HIV RNA, ART regimen, weight), and date of visit. An individual who had a follow-up period of <24 weeks or lacked a weight record at either study enrollment or 24 weeks after enrollment was excluded. If the weight record on a scheduled visit date was not available, we recorded the weight within the nearest 30 days before or after that date. The PIRC classified participants as having acute HIV infection when early antigen/nucleic acid positive and antibody negative/indeterminate (indexed to Fiebig stage classification I–II) and as having early HIV infection when the antibody was positive and the results of detuned assay were consistent with recent infection <170 days [23–25]. Viral suppression was defined as an HIV RNA of <200 copies/mL.

**Patient Consent Statement**

The UCSD Human Research Protections Program approved the study protocol. All participants provided written informed consent.

**Study Process**

For this analysis, we created 2 data sets, A and B (Figure 1). Data set A was built to describe the weight change and identify factors that may affect weight trajectory among people with AEH. Data set A recorded participants’ weight at study enrollment and at 12, 24, 48, 72, and 96 weeks thereafter. As most participants were enrolled immediately after HIV diagnosis, the

---

**Figure 1.** Study diagram. Abbreviation: ART, antiretroviral therapy.
time of enrollment was also considered the time of HIV diagnosis. Participants were further divided into an Early Treatment Group and Deferred Treatment Group according to whether they received ART within 96 weeks after HIV diagnosis. Both groups were censored either at 96 weeks or when the participant was lost to follow-up. We also used Data set A to identify potential variables associated with excessive weight gain, defined as a weight increase of ≥15% through 96 weeks after HIV diagnosis. A sensitivity analysis using different cutoff values for excessive weight gain of 18% and 12% was also performed.

Data set B included the participants in the Early Treatment Group and recorded weight since the time ART was initiated. The purpose of Data set B was to analyze the impact of antiretroviral agents on weight change. Data set B was censored either at 96 weeks after ART initiation or when participants switched ART classes (non-nucleoside reverse transcriptase inhibitor [NNRTI], protease inhibitor [PI], and INSTI), regardless of the nucleoside reverse transcriptase inhibitor (NRTI) components. The main NRTI components recorded in this study were primarily the initial NRTIs. If the initial NRTIs were taken for <24 weeks, then the NRTIs used for the longest time were considered the main NRTI components.

Statistical Analysis
In the descriptive analysis, the study used the chi-square or Fisher exact test for categorical variables, the Wilcoxon rank-sum test for continuous variables between 2 groups, and the Kruskal-Wallis test for continuous variables among ≥3 groups. For longitudinal data, we adopted multivariable mixed-effects linear regression models to compare differences in the slopes of weight gain over time between 2 specific groups of participants. Each comparison was performed using a separate model. Every participant’s repeated measurements were treated as the random effect, consisting of a random intercept allowing for individuals’ baseline differences and a random slope allowing for individuals’ differences in weight change over time. Additionally, each comparison was adjusted for relevant factors, such as age, race, ethnicity, CD4 count, HIV RNA, and ART component. The study used the logistic regression model to identify variables associated with excessive weight gain in univariable and multivariable analyses. A P value of <.05 was considered statistically significant. Stata Statistical Software, version 15.1 (StataCorp LLC, College Station, TX, USA), was used for all study analyses.

RESULTS
Overview of Participants
A total of 463 men were included in the study analysis (Data set A), with a median age of 33.7 years, CD4 count of 507 cells/μL, and log HIV RNA of 5.0 copies/mL at enrollment. Overall, 331 participants received ART treatment within 96 weeks of HIV diagnosis, and 130 participants received ART ≥96 weeks after HIV diagnosis; these were classified as the Early and Deferred Treatment Groups, respectively (Table 1). A low CD4 count of <200 cells/μL at study entry was noted in 12 participants (2.6%) and was more likely to occur in acute HIV infection than in early HIV infection (7 vs 5; P = .044). Temporal trends in participants’ age, baseline weight, HIV RNA, and CD4 count were not statistically different (Supplementary Figure 1). Individuals with acute HIV infection (n = 130, 28.1%) had a higher median log HIV RNA (5.7 vs 4.8 copies/mL; P < .001) and a lower median CD4 count (468 vs 523 cells/μL; P < .001) than those with early HIV infection (n = 333, 71.9%) (Supplementary Table 1).

Factors Associated With Weight Gain Over Time
The median weight gain among the 463 study participants (interquartile range [IQR]) was 1.8 (0.0 to 4.8) kg at 48 weeks and 2.7 (–0.5 to 5.9) kg at 96 weeks (Table 2). After adjusting for baseline demographics and clinical characteristics, there was no difference in the slope of weight gain over time between the Early and Deferred Treatment Groups, acute and early HIV infection, participants with study entry HIV RNA greater or less than 100,000 copies/mL, and participants with study entry CD4 counts greater or less than 350 cells/μL (Figure 2). There was also no difference in the slope of weight gain over time between persons in the Early Treatment Group and Deferred Treatment Group with baseline HIV RNA greater or less than 100,000 copies/mL, or baseline CD4 count greater or less than 350 cells/μL (Supplementary Figure 2). When the cutoff value for CD4 count was set to 200 cells/μL, more weight gain over time was observed in people with baseline CD4 counts <200 cells/μL than those with baseline CD4 counts ≥200 cells/μL (Supplementary Figure 3).

Factors Associated With Excessive Weight Increase
Excessive weight gain was observed in 71 (15.3%), 44 (9.5%), and 30 (6.5%) persons in Data set A using a definition of more than 12%, 15%, and 18% weight increase, respectively, from HIV diagnosis through 96 weeks. In the multivariable analysis, only INSTI-based ART (odds ratio, 1.87; 95% CI, 1.04–3.38; P = .037) was significantly associated with a weight gain of ≥12% through 96 weeks (Supplementary Tables 2 and 3). No variable was identified that was associated with a weight increase of more than 15% or 18% (Supplementary Tables 4 and 5).

How ART Regimens Affected Weight Gain
A total of 299 participants received ART within 96 weeks of study entry (median time from study entry to ART initiation, 3.9 weeks; ie, Early ART—Data set B), 72 with NNRTI-based (24.1%), 124 with PI-based (41.5%), and 95 with INSTI-based (31.8%) regimens (Table 3). The other 8 persons received triple-NRTI regimens without another agent. Efavirenz was the most commonly used NNRTI (67/72, 93.1%), and elvitegravir accounted for 77.9%
Among participants taking a PI, 48 received lopinavir (38.7%) and 41 received atazanavir (33.1%). A detailed distribution of ART regimens is listed in Supplementary Table 6.

The proportions of participants with viral suppression 24 weeks after treatment were not different by ART class (NNRTI, 95.8%; PI, 96.0%; INSTI, 97.9%; \( P = .567 \)). As for the NRTI component, the numbers of participants receiving tenofovir disoproxil fumarate (TDF), TAF, and other NRTIs were 178 (59.5%), 49 (16.4%), and 72 (24.1%), respectively (Table 3). The median length of time on ART was shorter for participants in the TAF group vs the non-TAF group (70.1 vs 89.4 weeks; \( P = .004 \)).

The median percent weight change at 96 weeks after ART initiation among NNRTI-, PI-, INSTI-based regimen users was 0.9%, 4.3%, and 4.9%, respectively (Table 4). After adjusting for baseline demographics and HIV clinical characteristics, weight gain over time was significantly greater among participants receiving INSTI-based regimens compared with NNRTI-based regimens (\( P = .012 \)) (Figure 3A). The slope of weight gain over time was not different between participants receiving INSTI vs PI, NNRTI vs PI, and TAF vs non-TAF regimens (\( P = .080, .163, .105 \), respectively) (Figure 3B, C, D).

Table 1. Demographics, Clinical Characteristics, and Antiretroviral Therapy Regimens of Participants (Results From Data Set A)

|                  | All (n = 463) | Early Treatment (n = 331) | Deferred Treatment (n = 132) | \( P \) Value |
|------------------|--------------|---------------------------|-----------------------------|-------------|
| Age at HIV diagnosis, median (IQR), y | 33.7 (26.9 to 41.5) | 34.1 (27.0 to 41.8) | 32.7 (26.6 to 39.8) | .236 |
| Race             |              |                           |                             | .316 |
| White, No. (%)   | 387 (83.6)   | 273 (82.5)                | 114 (86.4)                  |              |
| Black, No. (%)   | 25 (5.4)     | 17 (5.1)                  | 8 (6.1)                     |              |
| Hispanic ethnicity, No. (%) | 142 (31.1) | 106 (32.7) | 36 (27.3) | .255 |
| Year of HIV diagnosis, median (IQR) | 2005 (2003 to 2012) | 2006 (2003 to 2014) | 2004 (2003 to 2008) | <.001 |
| Acute HIV infection, No. (%) | 130 (28.1) | 100 (30.2) | 30 (22.7) | .106 |
| Time from HIV diagnosis to enrollment, median (IQR), wk | 0 (0 to 1.4) | 0 (0 to 1.1) | 0 (0 to 2.1) | .047 |
| Time from enrollment to initial ART, median (IQR), wk | 78 (2.1 to 37.6) | 4.9 (2.1 to 22.0) | 155.1 (118.7 to 233.0) | <.001 |
| Overall follow-up time, median (IQR), wk | 121.4 (71.6 to 203.9) | 112.7 (71.0 to 194.9) | 143.3 (77.9 to 248.4) | .009 |
| Baseline weight, median (IQR), kg | 75.8 (68.0 to 84.4) | 75.3 (67.6 to 85.3) | 76.2 (69.9 to 83.0) | .704 |
| Baseline CD4 count, median (IQR), cells/μL | 507 (390 to 649) | 490 (351 to 621) | 545 (463 to 750) | <.001 |
| <350 cells/μL, No. (%) | 90 (19.4) | 82 (24.8) | 8 (6.1) | <.001 |
| <200 cells/μL, No. (%) | 12 (2.6) | 12 (3.6) | 0 (0.0) | .023 |
| CD4 count at 24 wk after HIV diagnosis, median (IQR), cells/μL | 639 (474 to 809) | 657 (482 to 850) | 583 (467 to 738) | .033 |
| Baseline log HIV RNA, median (IQR), copies/mL | 5.0 (4.2 to 5.7) | 5.2 (4.6 to 5.9) | 4.4 (3.6 to 5.1) | <.001 |
| HIV RNA >100 000 copies/mL, No. (%) | 232 (50.1) | 194 (58.6) | 37 (28.0) | <.001 |
| Log HIV RNA at 24 wk after HIV diagnosis, median (IQR), copies/mL | 2.1 (1.6 to 4.4) | 1.7 (1.3 to 2.5) | 4.3 (3.3 to 4.9) | <.001 |
| Viral suppressed at 24 wk after HIV diagnosis, No. (%) | 251 (54.2) | 237 (71.6) | 14 (10.6) | <.001 |
| Initial ART class* |              |                           |                             |              |
| NNRTI-based, No. (%) | 84 (18.1) | 84 (25.4) | - |              |
| PI-based, No. (%) | 134 (28.9) | 134 (40.5) | - |              |
| INSTI-based, No. (%) | 96 (20.7) | 96 (29.0) | - |              |
| Other, No. (%) | 17 (3.7) | 17 (5.1) | - |              |
| Main NRTI component* |              |                           |                             |              |
| TDF | 200 (43.2) | 200 (60.4) | - |              |
| TAF | 49 (10.6) | 49 (14.8) | - |              |
| Other | 70 (15.1) | 70 (21.1) | - |              |
| Abbreviations: ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
| *ART initiated within 96 weeks after HIV diagnosis. |

Table 2. Median Percent Weight Change and Interquartile Range After HIV Diagnosis (Results From Data Set A)

| Time of visit | All (n = 463) | Early Treatment (n = 331) | Deferred Treatment (n = 132) | \( P \) Value |
|--------------|--------------|---------------------------|-----------------------------|-------------|
| Week 12 (n = 439) | 1.5 (-0.6 to 3.8) | 1.5 (-0.6 to 3.9) | 1.5 (-0.7 to 3.5) | .528 |
| Week 24 (n = 434) | 2.0 (-0.6 to 4.8) | 2.0 (-0.6 to 5.1) | 2.0 (-1.1 to 4.5) | .684 |
| Week 48 (n = 369) | 2.8 (0.0 to 6.3) | 3.0 (0.0 to 6.9) | 2.1 (-0.5 to 6.0) | .314 |
| Week 72 (n = 296) | 3.2 (0.0 to 7.9) | 3.4 (0.0 to 7.9) | 2.8 (0.0 to 7.9) | .690 |
| Week 96 (n = 267) | 3.8 (-0.6 to 8.1) | 4.3 (0.0 to 8.4) | 3.1 (-1.1 to 6.5) | .148 |
Weight Gain in Acute and Early HIV • OFID • 5

Figure 2. Predicted weight change from baseline between individuals with different variables, adjusted for age, race, ethnicity, baseline CD4 count, baseline HIV RNA, baseline weight, receiving antiretroviral therapy or not, and year of HIV diagnosis as adequate (results from Data set A). A, Early treatment vs deferred treatment (difference between slopes, \( P = .773 \)). B, Early HIV infection vs acute HIV infection (difference between slopes, \( P = .733 \)). C, Baseline HIV RNA \( \geq 100,000 \) copies/mL vs <100,000 copies/mL (difference between slopes, \( P = .101 \)). D, Baseline CD4 count <350 cells/µL vs ≥350 cells/µL (difference between slopes, \( P = .477 \)).

Table 3. Demographics and HIV-Related Clinical Characteristics of Participants Receiving Early Treatment by ART Class (Results From Data Set B)

|                      | All (n = 299) | NNRTI (n = 72) | PI (n = 124) | INSTI (n = 95) | \( P \) Value* |
|----------------------|--------------|---------------|--------------|---------------|---------------|
| Age at ART initiation, median (IQR), y | 34.6 (27.7 to 42.0) | 34.4 (28.3 to 42.9) | 36.1 (28.8 to 41.9) | 31.8 (26.3 to 40.8) | .152 |
| Race                 |              |               |              |               | .032           |
| White, No. (%)       | 249 (83.3)   | 64 (88.9)     | 108 (87.1)   | 69 (72.6)     |               |
| Black, No. (%)       | 16 (5.4)     | 3 (4.2)       | 6 (4.8)      | 7 (7.4)       |               |
| Hispanic ethnicity, No. (%) | 95 (31.8) | 19 (26.4)     | 22 (17.7)    | 51 (53.7)     | <.001          |
| Year of ART initiation, median (IQR) | 2005 (2003 to 2014) | 2003 (2002 to 2005) | 2004 (2002 to 2010) | 2016 (2015 to 2017) | <.001 |
| Weight at ART initiation, median (IQR), kg | 76.2 (68.0 to 86.0) | 76.2 (68.5 to 84.6) | 76.0 (68.9 to 84.1) | 74.4 (66.7 to 88.8) | .939 |
| CD4 count at ART initiation, median (IQR), cells/µL | 499 (366 to 674) | 492 (359 to 674) | 489 (355 to 619) | 541 (404 to 682) | .109 |
| CD4 count at 24 wk after ART initiation, median (IQR), cells/µL | 696 (525 to 865) | 574 (470 to 752) | 709 (549 to 862) | 753 (610 to 916) | <.001 |
| Log HIV RNA at ART initiation, median (IQR), copies/mL | 5.0 (4.5 to 5.6) | 4.8 (4.5 to 5.3) | 5.1 (4.7 to 5.8) | 5.0 (4.3 to 5.8) | .014 |
| Viral suppressed at 24 wk after ART initiation, No. (%) | 281 (96.3) | 69 (95.8) | 119 (96.0) | 93 (97.9) | .567 |
| Time from enrollment to ART initiation, median (IQR), wk | 3.9 (2.1 to 13.7) | 14.5 (7.1 to 32.1) | 3.4 (2.1 to 10.9) | 2.1 (2.0 to 4.0) | <.001 |
| Time of initial ART use, median (IQR), wk | 84.1 (48.6 to 126.0) | 91.3 (54.6 to 146.2) | 78.1 (48.9 to 106.3) | 86.6 (45.7 to 136.4) | .192 |
| Main NRTI component |              |               |              |               | <.001          |
| TDF, No. (%) | 178 (59.5) | 51 (70.8) | 78 (62.9) | 43 (45.3) |               |
| TAF, No. (%) | 49 (16.4) | 0 (0.0) | 0 (0.0) | 49 (51.6) |               |
| Other NRTI, No. (%) | 72 (24.1) | 21 (29.2) | 46 (37.1) | 3 (3.2) |               |

Abbreviations: ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

*Eight individuals who received NRTI only were not included for analysis.
DISCUSSION
This study demonstrated that the baseline HIV-related clinical characteristics, primarily the HIV RNA and CD4 count, were not significantly associated with weight gain among most men (>95%) with AEH. Neither an HIV RNA >100 000 copies/mL nor a CD4 count <350 cells/μL was associated with a higher rate of weight gain among participants overall, or for those either on or off ART. Only among the 2.6% of participants with CD4 counts <200 cells/μL at HIV diagnosis was weight gain greater than that observed among the comparators. Additionally, the Early Treatment Group participants did not gain more weight than those in the Deferred Treatment Group. These results suggest that, when initiating in the early stage of HIV disease, ART is not a significant contributor to greater weight gain.

Table 4. Median Percent Weight Change and Interquartile Range After ART Initiation (Results From Data Set B)

| Time of Visit | All (n = 299) | NNRTI (n = 72) | PI (n = 124) | INSTI (n = 95) | P Value
|---------------|---------------|---------------|---------------|---------------|----------|
| Week 12 (n = 281) | 1.3 (–0.7 to 3.3) | 0.0 (–1.0 to 2.8) | 1.3 (–0.9 to 3.3) | 1.5 (–0.3 to 3.9) | .284     |
| Week 24 (n = 267) | 1.3 (–1.0 to 4.0) | 0.6 (–1.4 to 3.1) | 1.0 (–1.3 to 3.3) | 2.1 (–0.7 to 5.1) | .082     |
| Week 48 (n = 232) | 2.1 (–1.0 to 5.8) | 1.0 (–2.4 to 5.2) | 2.6 (–1.0 to 5.4) | 2.2 (0.4 to 7.3) | .102     |
| Week 72 (n = 168) | 2.6 (–0.9 to 6.9) | 1.0 (–0.6 to 3.0) | 2.6 (–1.3 to 6.6) | 4.6 (–0.2 to 10.6) | .018     |
| Week 96 (n = 149) | 3.6 (0.0 to 7.9) | 0.9 (–3.6 to 5.8) | 4.3 (1.5 to 7.8) | 4.9 (–0.3 to 10.4) | .016     |

Abbreviations: ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

*Eight individuals who received NRTI only were not included for analysis.

Figure 3. Predicted weight change from ART initiation between individuals receiving different ART components, adjusted for age, race, ethnicity, CD4 T-cell count at ART initiation, HIV RNA at ART initiation, weight at ART initiation, year of HIV diagnosis, main NRTI component, and ART class (results from Data set B). A, INSTI-based vs NNRTI-based ART (difference between slopes, P = .012). B, INSTI-based vs PI-based ART (difference between slopes, P = .080). C, PI-based vs NNRTI-based ART (difference between slopes, P = .168). D, TAF-containing vs non-TAF-NRTI-containing ART (difference between slopes, P = .105). Abbreviations: ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TAF, tenofovir alafenamide.
HIV RNA and CD4 count have been identified as strong predictors of weight change in previous reports [1, 5, 6, 12, 15]. There are 2 possible explanations of why we did not observe similar findings. First, weight is less influenced by HIV infection in AEH than in chronic HIV infection; the duration of infection may not be sufficient for these clinical characteristics to influence weight. Second, CD4 count and HIV RNA dynamics are unique in AEH. In AEH, Le and colleagues observed a spontaneous restoration of CD4 counts in the initial 4-month window after HIV infection, followed by a progressive decline [23]. Another study revealed that peak and nadir viremia occurred at a median of 13 and 31 days after HIV RNA being detected, respectively [26]. The nonlinear nature of CD4 counts and HIV RNA during AEH may weaken their associations with weight change.

Taking an INSTI-based regimen was the single most sensitive predictor for an excessive weight increase in this study. Besides, similar to several previous reports [1, 4, 9, 12], our findings show that INSTI users had greater weight gain than NNRTI users, even though the most prevalent INSTI in our study was elvitegravir, which was associated with less weight gain than dolutegravir or bictegravir [1, 9]. These findings may partly be explained by the effect of efavirenz on weight suppression as efavirenz accounted for 93% of NNRTIs in this study [27, 28]. Our results did not, however, support the hypothesis that the greater weight gain caused by INSTI was due to a more rapid return-to-health effect. The proportions of participants with viral suppression at 24 weeks after treatment were similar by ART class. The greater CD4 count increase among INSTI users was most likely due to the shorter duration from HIV diagnosis to ART initiation, which was associated with an enhanced CD4 count recovery [23]. In previous reports without a noticeable return-to-health effect, such as regimen-switching studies among virally suppressed populations [29, 30], INSTI users still had a greater weight gain than NNRTI users. Further research is needed to clarify the mechanism underlying INSTI-based weight gain.

TAF use compared with non-TAF use demonstrated only a trend toward greater weight gain in this study population. This observation is in contrast to previous reports showing that TAF use was associated with greater weight gain than non-TAF NRTI use [31–33]. Several reasons may explain the discrepancy. First, we censored our weight record in Data set B only when participants switched ART classes, not when they switched NRTI components. Therefore, participants who initially started TDF-containing regimens and then switched to TAF-containing regimens were still categorized in the TDF group. Second, the median length of time on ART was significantly shorter for participants in the TAF group vs the non-TAF group. Third, all TAF users took INSTIs at the same time, and INSTIs were associated with excessive weight gain in this study. The effect of INSTIs on weight change may also influence the results of the analysis between the TAF and non-TAF groups. Finally, only 16.4% of the study participants received TAF. Collectively, these explanations suggest that the power to discriminate between the TAF and non-TAF groups may be limited. Thus, our results cannot confidently conclude that weight gain over time did not differ between TAF users and non-TAF-NRTI users.

There were several limitations to this study. First, participants were mainly white men. The results may not be generalizable to women and Blacks. Second, baseline height was available in only a small proportion of participants. Therefore, we cannot calculate BMI for better categorization and adjustment. Instead of BMI or absolute weight change, the percentage of weight change was used in most of our analyses. Third, our study did not include other factors that may influence weight change, such as dietary habits, physical activity, concomitant disease and medications, and smoking. In addition, ~78% of the INSTI use was elvitegravir, which has been associated with less weight gain [1, 9], so our findings may not be representative of dolutegravir or bictegravir use. Last, all TAF users took INSTIs simultaneously, and about half of INSTI users took TAF at the same time. Therefore, even after statistical adjustment, we may not be able to separate the effects of TAF and INSTI on weight gain completely.

To conclude, the influence of the ART regimen outweighed that of HIV-related clinical characteristics on weight gain in the acute and early stages of HIV infection. As more PWH were diagnosed at an earlier stage of HIV infection and INSTI-based regimens are almost universally recommended as initial ART [34], the role of ART regimen on weight gain will become even more crucial.

**Supplementary Data**

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Acknowledgments**

The authors acknowledge all participants of the PIRC program and the members of the AntiViral Research Center who contributed to the study. Financial support. This work was supported by grants from the National Institutes of Health (NIH): R01 MH100974 and R24 AI106039. Antiretroviral treatment was provided at no cost to many study participants as part of a Gilead Sciences Investigator-Sponsored Research Grant (IN-US-292–4217); Gilead Sciences had no role in the development or conduct of the study.

Potential conflicts of interest. Susan J. Little received an honorarium and travel support from Gilead Sciences. She also received grant support paid to her institution from Gilead Sciences. All other authors reported no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Sax PE, Erlendson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis 2020;71:1379–89.
2. Koethe JR, Jenkins CA, Lau R, et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Rising obesity prevalence and weight

---

**Disclosure of Potential Conflicts of Interest.**

Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**Financial support.** This work was supported by grants from the National Institutes of Health (NIH): R01 MH100974 and R24 AI106039. Antiretroviral treatment was provided at no cost to many study participants as part of a Gilead Sciences Investigator-Sponsored Research Grant (IN-US-292–4217); Gilead Sciences had no role in the development or conduct of the study.

**Potential conflicts of interest.** Susan J. Little received an honorarium and travel support from Gilead Sciences. She also received grant support paid to her institution from Gilead Sciences. All other authors reported no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**Supplementary Data**

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses 2016; 32:50–8.

3. Brennan AT, Berry KM, Rosen S, et al. Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. AIDS 2019; 33:2049–59.

4. Bourgi K, Jenkins CA, Rebeiro PF, et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc 2020; 23:e25484.

5. Crum-Cianflone N, Rodiger MP, Eberly L, et al; Infectious Disease Clinical Research Program HIV Working Group. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One 2010; 5:e10106.

6. Mwamburi DM, Wilson IB, Jacobson DL, et al. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:167–73.

7. Wanke CA, Silva M, Knox TA, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 31:803–5.

8. Baker JV, Sharma S, Achhra AC, et al. Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-positive participants in the START (Strategic Timing of Antiretroviral Treatment) trial. J Am Heart Assoc 2017; 6:e004987.

9. Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment-naïve persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis 2020; 70:1267–74.

10. Venker NDE, Mootherhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med 2019; 381:803–15.

11. Kounafrack C, Mpoou-Itame M, Omegha Bassega P, et al. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N Engl J Med 2019; 381:816–26.

12. Bakal DR, Coelho LE, Luz PM, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-ART-specific risk factors. J Antimicrob Chemother 2018; 73:2177–85.

13. Baran SH, Smeaton LM, Xu A, et al. HIV-infected women gain more weight than men following the initiation of antiretroviral therapy. J Womens Health (Larchmt) 2018; 27:1162–9.

14. Erlandson KM, Zhang L, Lake JE, et al. Changes in weight and weight distribution across the lifespan among HIV-infected and -uninfected men and women. Medicine (Baltimore) 2016; 95:e5399.

15. Haase B, Ift M, Ledergerber B, et al. Obesity trends and body mass index changes after starting antiretroviral treatment: the Swiss HIV Cohort Study. Open Forum Infect Dis 2014; 1:XXX–XX.

16. Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis 2020; 33:10–9.

17. Yuh B, Tate J, Butt AA, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis 2015; 60:1852–9.

18. Ballin SS, Gabriel CL, Wajjalla CN, Kosthe JR. Obesity and weight gain in persons with HIV. Curr HIV/AIDS Rep 2020; 17:138–50.

19. Herrin M, Tate JF, Alegun KM, et al. Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J Acquir Immune Defic Syndr 2016; 73:228–36.

20. Achhra AC, Mocroft A, Reiss P, et al; D:A:D Study Group. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med 2016; 17:255–68.

21. Achhra AC, Sabin C, Ryan L, et al; D:A:D Study Group. Body mass index and the risk of serious non-AIDS events and all-cause mortality in treated HIV-positive individuals: D:A:D cohort analysis. J Acquir Immune Defic Syndr 2018; 78:579–88.

22. Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front Endocrinol (Lausanne) 2018; 9:705.

23. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368:218–30.

24. Martin TCS, Abrams M, Anderson C, Little SJ. Rapid antiretroviral therapy among individuals with acute and early HIV. [published online ahead of print 10 August 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ciaa1174.

25. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871–9.

26. Robb ML, Eller LA, Kibulka H, et al; BV 217 Study Team. Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N Engl J Med 2019; 374:2120–30.

27. Greisel R, Maertens G, Chirehwa M, et al. CYP2B6 genotype and weight gain differences between dolutegravir and efavirenz. [published online ahead of print 22 September 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ciaa1073.

28. Leonard MA, Cindi Z, Bradford Y, et al. Efavirenz pharmacogenetics and weight gain following switch to integrase inhibitor-containing regimens. [published online ahead of print 23 August 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ciaa1219.

29. Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Dis 2020; 71:e471–7.

30. Norwood J, Turner M, Bofill C, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr 2017; 76:527–31.

31. Taramasso L, Berruti M, Briano F, Di Biagio A. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. AIDS 2020; 34:877–81.

32. Schafer JJ, Sassa KN, O’Connor JR, et al. Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Open Forum Infect Dis 2019; 6:XXX–XX.

33. Gomez M, Seybold U, Roeder J, et al. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)-to-a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017. Infection 2019; 47:95–102.

34. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. Accessed 21 September 2020.